Stem definition | Drug id | CAS RN |
---|---|---|
peptides and glycopeptides | 1546 | 108736-35-2 |
Dose | Unit | Route |
---|---|---|
3 | mg | P |
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 0.20 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 5.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.03 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 30, 2007 | FDA | IPSEN PHARMA | |
Dec. 12, 2020 | PMDA | TEIJIN PHARMA LIMITED |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Inappropriate schedule of product administration | 303.28 | 19.56 | 173 | 8224 | 71658 | 50525069 |
Injection site mass | 193.60 | 19.56 | 79 | 8318 | 15601 | 50581126 |
Insulin-like growth factor increased | 193.37 | 19.56 | 41 | 8356 | 777 | 50595950 |
Diarrhoea | 156.85 | 19.56 | 317 | 8080 | 588159 | 50008568 |
Injection site pain | 120.16 | 19.56 | 118 | 8279 | 110906 | 50485821 |
Cholelithiasis | 102.68 | 19.56 | 69 | 8328 | 37904 | 50558823 |
Abdominal pain | 89.89 | 19.56 | 149 | 8248 | 236079 | 50360648 |
Blood growth hormone increased | 86.89 | 19.56 | 19 | 8378 | 418 | 50596309 |
Flatulence | 83.17 | 19.56 | 55 | 8342 | 29403 | 50567324 |
Abdominal distension | 79.73 | 19.56 | 78 | 8319 | 72825 | 50523902 |
Neoplasm progression | 74.09 | 19.56 | 51 | 8346 | 29106 | 50567621 |
Off label use | 55.10 | 19.56 | 188 | 8209 | 474238 | 50122489 |
Disease progression | 52.81 | 19.56 | 72 | 8325 | 95794 | 50500933 |
Injection site nodule | 52.25 | 19.56 | 20 | 8377 | 3328 | 50593399 |
Carcinoid tumour pulmonary | 44.68 | 19.56 | 11 | 8386 | 412 | 50596315 |
Carcinoid crisis | 40.17 | 19.56 | 9 | 8388 | 222 | 50596505 |
Intestinal obstruction | 40.12 | 19.56 | 34 | 8363 | 26349 | 50570378 |
Blood glucose increased | 39.91 | 19.56 | 54 | 8343 | 71270 | 50525457 |
Abdominal pain upper | 38.59 | 19.56 | 83 | 8314 | 159226 | 50437501 |
Product dose omission issue | 38.09 | 19.56 | 90 | 8307 | 183748 | 50412979 |
Terminal state | 38.00 | 19.56 | 14 | 8383 | 2096 | 50594631 |
Weight decreased | 36.16 | 19.56 | 99 | 8298 | 221146 | 50375581 |
Hypoglycaemia | 35.33 | 19.56 | 44 | 8353 | 53537 | 50543190 |
Blood glucose decreased | 35.19 | 19.56 | 27 | 8370 | 18184 | 50578543 |
Nausea | 34.61 | 19.56 | 217 | 8180 | 705181 | 49891546 |
Needle issue | 34.59 | 19.56 | 19 | 8378 | 7256 | 50589471 |
Insulinoma | 30.77 | 19.56 | 6 | 8391 | 73 | 50596654 |
Asthenia | 30.59 | 19.56 | 119 | 8278 | 318923 | 50277804 |
Incorrect route of product administration | 30.34 | 19.56 | 25 | 8372 | 18641 | 50578086 |
Steatorrhoea | 30.33 | 19.56 | 8 | 8389 | 396 | 50596331 |
Product administered at inappropriate site | 29.07 | 19.56 | 12 | 8385 | 2431 | 50594296 |
Carcinoid syndrome | 28.68 | 19.56 | 6 | 8391 | 106 | 50596621 |
Menopausal symptoms | 27.62 | 19.56 | 11 | 8386 | 2032 | 50594695 |
Bronchiolitis | 25.99 | 19.56 | 11 | 8386 | 2370 | 50594357 |
Pituitary tumour removal | 24.59 | 19.56 | 4 | 8393 | 15 | 50596712 |
Drug hypersensitivity | 24.10 | 19.56 | 6 | 8391 | 251004 | 50345723 |
Vomiting | 23.90 | 19.56 | 144 | 8253 | 460614 | 50136113 |
Blood chromogranin A increased | 23.82 | 19.56 | 6 | 8391 | 247 | 50596480 |
Flushing | 23.67 | 19.56 | 41 | 8356 | 66974 | 50529753 |
Faeces pale | 23.60 | 19.56 | 9 | 8388 | 1482 | 50595245 |
Injection site haemorrhage | 23.59 | 19.56 | 23 | 8374 | 21323 | 50575404 |
Constipation | 23.55 | 19.56 | 76 | 8321 | 185632 | 50411095 |
Postoperative adhesion | 23.37 | 19.56 | 6 | 8391 | 267 | 50596460 |
Injection site pruritus | 23.20 | 19.56 | 31 | 8366 | 40380 | 50556347 |
Malaise | 22.86 | 19.56 | 113 | 8284 | 335419 | 50261308 |
Gastroenteropancreatic neuroendocrine tumour disease | 22.63 | 19.56 | 4 | 8393 | 27 | 50596700 |
Toxicity to various agents | 22.61 | 19.56 | 4 | 8393 | 212495 | 50384232 |
Thyroid neoplasm | 21.92 | 19.56 | 11 | 8386 | 3496 | 50593231 |
Malignant neoplasm progression | 21.90 | 19.56 | 40 | 8357 | 68084 | 50528643 |
Muscle neoplasm | 21.61 | 19.56 | 4 | 8393 | 36 | 50596691 |
Neoplasm | 21.55 | 19.56 | 13 | 8384 | 5915 | 50590812 |
Injection site hypoaesthesia | 21.37 | 19.56 | 6 | 8391 | 376 | 50596351 |
Gallbladder neoplasm | 21.32 | 19.56 | 4 | 8393 | 39 | 50596688 |
Lymphatic system neoplasm | 21.23 | 19.56 | 4 | 8393 | 40 | 50596687 |
Biliary dilatation | 21.17 | 19.56 | 9 | 8388 | 1960 | 50594767 |
Metastases to liver | 20.99 | 19.56 | 21 | 8376 | 20083 | 50576644 |
Spleen disorder | 20.69 | 19.56 | 7 | 8390 | 817 | 50595910 |
Decreased appetite | 20.07 | 19.56 | 76 | 8321 | 200847 | 50395880 |
Body height increased | 19.93 | 19.56 | 4 | 8393 | 57 | 50596670 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Inappropriate schedule of product administration | 194.51 | 21.79 | 113 | 5245 | 44359 | 29524810 |
Diarrhoea | 153.56 | 21.79 | 239 | 5119 | 332459 | 29236710 |
Injection site pain | 137.89 | 21.79 | 81 | 5277 | 32365 | 29536804 |
Insulin-like growth factor increased | 135.59 | 21.79 | 33 | 5325 | 1078 | 29568091 |
Neoplasm progression | 116.40 | 21.79 | 60 | 5298 | 18552 | 29550617 |
Injection site mass | 105.46 | 21.79 | 39 | 5319 | 5416 | 29563753 |
Abdominal pain | 84.90 | 21.79 | 113 | 5245 | 135244 | 29433925 |
Flatulence | 74.58 | 21.79 | 44 | 5314 | 17665 | 29551504 |
Injection site haemorrhage | 70.20 | 21.79 | 33 | 5325 | 8353 | 29560816 |
Disease progression | 68.32 | 21.79 | 79 | 5279 | 81837 | 29487332 |
Off label use | 67.88 | 21.79 | 160 | 5198 | 300640 | 29268529 |
Cholelithiasis | 67.32 | 21.79 | 42 | 5316 | 18630 | 29550539 |
Carcinoid heart disease | 60.93 | 21.79 | 9 | 5349 | 12 | 29569157 |
Incorrect route of product administration | 48.53 | 21.79 | 28 | 5330 | 10773 | 29558396 |
Pituitary tumour removal | 38.08 | 21.79 | 5 | 5353 | 0 | 29569169 |
Injection site nodule | 33.98 | 21.79 | 12 | 5346 | 1458 | 29567711 |
Terminal state | 33.13 | 21.79 | 15 | 5343 | 3479 | 29565690 |
Injection site abscess | 29.38 | 21.79 | 9 | 5349 | 700 | 29568469 |
Abdominal pain upper | 29.35 | 21.79 | 45 | 5313 | 60948 | 29508221 |
Pancreatic neuroendocrine tumour metastatic | 29.21 | 21.79 | 6 | 5352 | 88 | 29569081 |
Pituitary tumour benign | 28.47 | 21.79 | 9 | 5349 | 777 | 29568392 |
Hepatic neoplasm | 27.83 | 21.79 | 11 | 5347 | 1825 | 29567344 |
Metastases to liver | 26.80 | 21.79 | 20 | 5338 | 11836 | 29557333 |
Insulin-like growth factor abnormal | 26.80 | 21.79 | 4 | 5354 | 6 | 29569163 |
Abdominal distension | 26.62 | 21.79 | 37 | 5321 | 45874 | 29523295 |
Steatorrhoea | 25.36 | 21.79 | 8 | 5350 | 686 | 29568483 |
Keratitis | 24.65 | 21.79 | 9 | 5349 | 1203 | 29567966 |
Hepatic pain | 24.55 | 21.79 | 9 | 5349 | 1216 | 29567953 |
Product dose omission issue | 24.55 | 21.79 | 54 | 5304 | 96329 | 29472840 |
Growth hormone deficiency | 23.86 | 21.79 | 6 | 5352 | 224 | 29568945 |
Carcinoid crisis | 23.69 | 21.79 | 6 | 5352 | 231 | 29568938 |
Asthenia | 22.84 | 21.79 | 88 | 5270 | 215162 | 29354007 |
Nausea | 22.07 | 21.79 | 107 | 5251 | 289148 | 29280021 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Inappropriate schedule of product administration | 308.14 | 18.42 | 197 | 11418 | 92089 | 64395028 |
Insulin-like growth factor increased | 232.51 | 18.42 | 55 | 11560 | 1597 | 64485520 |
Diarrhoea | 230.34 | 18.42 | 440 | 11175 | 722264 | 63764853 |
Injection site mass | 173.45 | 18.42 | 77 | 11538 | 17193 | 64469924 |
Injection site pain | 172.56 | 18.42 | 150 | 11465 | 111258 | 64375859 |
Abdominal pain | 157.19 | 18.42 | 234 | 11381 | 312141 | 64174976 |
Flatulence | 143.82 | 18.42 | 86 | 11529 | 35580 | 64451537 |
Neoplasm progression | 137.81 | 18.42 | 88 | 11527 | 40876 | 64446241 |
Cholelithiasis | 129.37 | 18.42 | 88 | 11527 | 45418 | 64441699 |
Abdominal distension | 91.35 | 18.42 | 99 | 11516 | 95895 | 64391222 |
Off label use | 81.46 | 18.42 | 274 | 11341 | 632532 | 63854585 |
Disease progression | 78.03 | 18.42 | 111 | 11504 | 141569 | 64345548 |
Injection site nodule | 65.88 | 18.42 | 24 | 11591 | 3206 | 64483911 |
Blood growth hormone increased | 58.58 | 18.42 | 15 | 11600 | 607 | 64486510 |
Terminal state | 58.44 | 18.42 | 24 | 11591 | 4420 | 64482697 |
Injection site haemorrhage | 57.46 | 18.42 | 42 | 11573 | 24236 | 64462881 |
Weight decreased | 54.98 | 18.42 | 143 | 11472 | 285596 | 64201521 |
Pituitary tumour removal | 51.25 | 18.42 | 8 | 11607 | 19 | 64487098 |
Intestinal obstruction | 50.37 | 18.42 | 46 | 11569 | 36240 | 64450877 |
Nausea | 50.00 | 18.42 | 275 | 11340 | 785525 | 63701592 |
Abdominal pain upper | 49.52 | 18.42 | 102 | 11513 | 174928 | 64312189 |
Asthenia | 49.34 | 18.42 | 179 | 11436 | 427865 | 64059252 |
Incorrect route of product administration | 47.79 | 18.42 | 37 | 11578 | 23261 | 64463856 |
Product dose omission issue | 47.65 | 18.42 | 107 | 11508 | 194640 | 64292477 |
Blood glucose increased | 46.97 | 18.42 | 72 | 11543 | 98001 | 64389116 |
Carcinoid tumour pulmonary | 46.40 | 18.42 | 11 | 11604 | 322 | 64486795 |
Carcinoid heart disease | 45.71 | 18.42 | 8 | 11607 | 46 | 64487071 |
Metastases to liver | 42.65 | 18.42 | 35 | 11580 | 23906 | 64463211 |
Injection site abscess | 42.52 | 18.42 | 14 | 11601 | 1384 | 64485733 |
Steatorrhoea | 41.43 | 18.42 | 12 | 11603 | 774 | 64486343 |
Malignant neoplasm progression | 40.78 | 18.42 | 73 | 11542 | 112798 | 64374319 |
Blood chromogranin A increased | 39.79 | 18.42 | 10 | 11605 | 375 | 64486742 |
Hepatic neoplasm | 38.37 | 18.42 | 16 | 11599 | 3061 | 64484056 |
Carcinoid crisis | 38.15 | 18.42 | 10 | 11605 | 444 | 64486673 |
Vomiting | 37.73 | 18.42 | 197 | 11418 | 550920 | 63936197 |
Blood glucose decreased | 37.45 | 18.42 | 32 | 11583 | 23091 | 64464026 |
Insulin-like growth factor abnormal | 36.29 | 18.42 | 6 | 11609 | 23 | 64487094 |
Insulinoma | 34.83 | 18.42 | 7 | 11608 | 92 | 64487025 |
Hypoglycaemia | 33.57 | 18.42 | 59 | 11556 | 89833 | 64397284 |
Drug interaction | 33.02 | 18.42 | 12 | 11603 | 362071 | 64125046 |
Constipation | 31.68 | 18.42 | 102 | 11513 | 229235 | 64257882 |
Flushing | 31.17 | 18.42 | 53 | 11562 | 78595 | 64408522 |
Menopausal symptoms | 29.43 | 18.42 | 11 | 11604 | 1579 | 64485538 |
Drug hypersensitivity | 29.41 | 18.42 | 4 | 11611 | 237811 | 64249306 |
Pituitary tumour | 29.37 | 18.42 | 10 | 11605 | 1096 | 64486021 |
Needle issue | 28.89 | 18.42 | 19 | 11596 | 9253 | 64477864 |
Pituitary tumour benign | 28.85 | 18.42 | 12 | 11603 | 2281 | 64484836 |
Metastases to bone | 28.54 | 18.42 | 26 | 11589 | 20409 | 64466708 |
Faeces pale | 27.53 | 18.42 | 12 | 11603 | 2559 | 64484558 |
Thyroid neoplasm | 27.15 | 18.42 | 12 | 11603 | 2645 | 64484472 |
Carcinoid syndrome | 26.06 | 18.42 | 6 | 11609 | 154 | 64486963 |
Growth hormone deficiency | 26.02 | 18.42 | 7 | 11608 | 344 | 64486773 |
Biliary obstruction | 25.76 | 18.42 | 13 | 11602 | 3851 | 64483266 |
Tumour necrosis | 25.12 | 18.42 | 10 | 11605 | 1699 | 64485418 |
Injection site hypoaesthesia | 24.89 | 18.42 | 7 | 11608 | 406 | 64486711 |
Gallbladder neoplasm | 24.45 | 18.42 | 5 | 11610 | 72 | 64487045 |
Acromegaly | 24.02 | 18.42 | 5 | 11610 | 79 | 64487038 |
Hepatic pain | 23.97 | 18.42 | 12 | 11603 | 3496 | 64483621 |
Pneumonia | 23.05 | 18.42 | 41 | 11574 | 559535 | 63927582 |
Hepatic embolisation | 22.71 | 18.42 | 4 | 11611 | 24 | 64487093 |
Injection site induration | 22.37 | 18.42 | 16 | 11599 | 8916 | 64478201 |
Gastroenteropancreatic neuroendocrine tumour disease | 21.94 | 18.42 | 4 | 11611 | 30 | 64487087 |
Keratitis | 21.90 | 18.42 | 11 | 11604 | 3226 | 64483891 |
Postoperative adhesion | 21.79 | 18.42 | 6 | 11609 | 322 | 64486795 |
Hepatobiliary disease | 21.71 | 18.42 | 7 | 11608 | 647 | 64486470 |
Hormone level abnormal | 21.65 | 18.42 | 9 | 11606 | 1708 | 64485409 |
Rash | 21.32 | 18.42 | 31 | 11584 | 458518 | 64028599 |
Biliary colic | 21.26 | 18.42 | 11 | 11604 | 3433 | 64483684 |
Headache | 21.05 | 18.42 | 165 | 11450 | 529302 | 63957815 |
Neoplasm | 20.92 | 18.42 | 14 | 11601 | 7017 | 64480100 |
Decreased appetite | 20.87 | 18.42 | 103 | 11512 | 281186 | 64205931 |
Bronchiolitis | 20.68 | 18.42 | 11 | 11604 | 3630 | 64483487 |
Lymphatic system neoplasm | 20.56 | 18.42 | 4 | 11611 | 44 | 64487073 |
Bile duct stone | 20.03 | 18.42 | 12 | 11603 | 4966 | 64482151 |
Cholecystitis | 19.96 | 18.42 | 21 | 11594 | 19615 | 64467502 |
Muscle neoplasm | 19.94 | 18.42 | 4 | 11611 | 52 | 64487065 |
Injection site pruritus | 19.84 | 18.42 | 29 | 11586 | 37797 | 64449320 |
Fatigue | 19.50 | 18.42 | 213 | 11402 | 748517 | 63738600 |
Malaise | 19.49 | 18.42 | 130 | 11485 | 396117 | 64091000 |
Product administered at inappropriate site | 19.39 | 18.42 | 10 | 11605 | 3100 | 64484017 |
Biliary dilatation | 19.25 | 18.42 | 9 | 11606 | 2259 | 64484858 |
None
Source | Code | Description |
---|---|---|
ATC | H01CB03 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES HYPOTHALAMIC HORMONES Somatostatin and analogues |
FDA MoA | N0000000194 | Somatostatin Receptor Agonists |
MeSH PA | D000970 | Antineoplastic Agents |
FDA EPC | N0000175904 | Somatostatin Analog |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Acromegaly | indication | 74107003 | DOID:2449 |
Hypersomatotropic gigantism | indication | 86073008 | |
Thyroid-stimulating hormone secreting pituitary tumour | indication | 127024001 | DOID:1785 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
Hypothyroidism | contraindication | 40930008 | DOID:1459 |
Bradycardia | contraindication | 48867003 | |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Impaired renal function disorder | contraindication | 197663003 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Hypoglycemic disorder | contraindication | 237630007 | |
Calculus in biliary tract | contraindication | 266474003 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.65 | acidic |
pKa2 | 12.16 | acidic |
pKa3 | 12.71 | acidic |
pKa4 | 13.18 | acidic |
pKa5 | 13.43 | acidic |
pKa6 | 13.67 | acidic |
pKa7 | 10.31 | Basic |
pKa8 | 6.97 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML) | SOMATULINE DEPOT | IPSEN PHARMA | N022074 | Aug. 30, 2007 | RX | SOLUTION | SUBCUTANEOUS | Sept. 15, 2024 | TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY |
EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML) | SOMATULINE DEPOT | IPSEN PHARMA | N022074 | Aug. 30, 2007 | RX | SOLUTION | SUBCUTANEOUS | Sept. 15, 2024 | TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY |
EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML) | SOMATULINE DEPOT | IPSEN PHARMA | N022074 | Aug. 30, 2007 | RX | SOLUTION | SUBCUTANEOUS | Sept. 15, 2024 | TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Somatostatin receptor type 2 | GPCR | AGONIST | Ki | 9.60 | IUPHAR | CHEMBL | |||
Somatostatin receptor type 5 | GPCR | AGONIST | Ki | 9.30 | IUPHAR | CHEMBL | |||
Somatostatin receptor type 1 | GPCR | Ki | 6.30 | PDSP | |||||
Somatostatin receptor type 4 | GPCR | Ki | 7.18 | PDSP | |||||
Somatostatin receptor type 3 | GPCR | AGONIST | Ki | 8 | IUPHAR | ||||
Somatostatin receptor type 2 | GPCR | AGONIST | Ki | 9.10 | IUPHAR | ||||
Somatostatin receptor type 3 | GPCR | AGONIST | IC50 | 8.20 | IUPHAR | ||||
Somatostatin receptor type 5 | GPCR | AGONIST | Ki | 7.60 | IUPHAR | ||||
Somatostatin receptor type 2 | GPCR | AGONIST | Ki | 8.80 | IUPHAR | ||||
Somatostatin receptor type 3 | GPCR | AGONIST | Ki | 6.90 | IUPHAR |
ID | Source |
---|---|
4026631 | VUID |
N0000179366 | NUI |
D04666 | KEGG_DRUG |
127984-74-1 | SECONDARY_CAS_RN |
4026631 | VANDF |
C0209211 | UMLSCUI |
CHEBI:135901 | CHEBI |
CHEMBL1201185 | ChEMBL_ID |
CHEMBL1201184 | ChEMBL_ID |
DB06791 | DRUGBANK_ID |
C060347 | MESH_SUPPLEMENTAL_RECORD_UI |
2031 | IUPHAR_LIGAND_ID |
6649 | INN_ID |
0G3DE8943Y | UNII |
6918011 | PUBCHEM_CID |
236167 | RXNORM |
18121 | MMSL |
354365 | MMSL |
d04961 | MMSL |
005272 | NDDF |
005273 | NDDF |
327379003 | SNOMEDCT_US |
395765000 | SNOMEDCT_US |
429611006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
SOMATULINE DEPOT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 15054-1060 | INJECTION | 60 mg | SUBCUTANEOUS | NDA | 29 sections |
SOMATULINE DEPOT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 15054-1060 | INJECTION | 60 mg | SUBCUTANEOUS | NDA | 29 sections |
SOMATULINE DEPOT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 15054-1090 | INJECTION | 90 mg | SUBCUTANEOUS | NDA | 29 sections |
SOMATULINE DEPOT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 15054-1090 | INJECTION | 90 mg | SUBCUTANEOUS | NDA | 29 sections |
SOMATULINE DEPOT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 15054-1120 | INJECTION | 120 mg | SUBCUTANEOUS | NDA | 29 sections |
SOMATULINE DEPOT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 15054-1120 | INJECTION | 120 mg | SUBCUTANEOUS | NDA | 29 sections |
Lanreotide Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-870 | INJECTION | 120 mg | SUBCUTANEOUS | NDA | 26 sections |
Lanreotide Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-880 | INJECTION | 60 mg | SUBCUTANEOUS | NDA | 26 sections |
Lanreotide Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-890 | INJECTION | 90 mg | SUBCUTANEOUS | NDA | 26 sections |